Naoto Okada1,2, Takeshi Hanafusa3, Shinji Abe4, Chiemi Sato4, Toshimi Nakamura5, Kazuhiko Teraoka5, Masahiro Abe6, Kazuyoshi Kawazoe4, Keisuke Ishizawa5,7. 1. Department of Clinical Pharmacy Practice Pedagogy Institute of Biomedical Sciences, Tokushima University Graduate School, 1-78-1 Shomachi, Tokushima, 770-8505, Japan. naoto-o@tokushima-u.ac.jp. 2. Department of Pharmacy, Tokushima University Hospital, 2-50-1 Kuramoto, Tokushima, 770-8503, Japan. naoto-o@tokushima-u.ac.jp. 3. Faculty of Pharmaceutical Sciences, University of Tokushima, Shomachi-1, Tokushima, 770-8505, Japan. 4. Department of Clinical Pharmacy Practice Pedagogy Institute of Biomedical Sciences, Tokushima University Graduate School, 1-78-1 Shomachi, Tokushima, 770-8505, Japan. 5. Department of Pharmacy, Tokushima University Hospital, 2-50-1 Kuramoto, Tokushima, 770-8503, Japan. 6. Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-8-15 Kuramoto, Tokushima, 770-8503, Japan. 7. Department of Clinical Pharmacy, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-8-15 Kuramoto, Tokushima, 770-8503, Japan.
Abstract
PURPOSE: Dysgeusia is one of the sporadic adverse effects induced by chemotherapy, but it remains poorly understood. The aim of this study was to retrospectively identify the risk factors related with dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation (AHSCT). METHODS: Forty-eight patients with myeloma or lymphoma undergoing AHSCT were enrolled in this study. Data regarding dysgeusia and symptoms were collected by interviews conducted by medical workers. Patient characteristics and unfavorable effects induced by dysgeusia were obtained from medical records and analyzed. Logistic regression analysis was performed to identify the risk factors related with dysgeusia. RESULTS: Of the 48 patients, 20 (42 %) had dysgeusia after AHSCT. The total period of parenteral nutrition (TPN) administration and period of decreased oral intake in the dysgeusia group were statistically longer than those in the non-dysgeusia group. Multivariate analyses revealed that oral mucositis (odds ratio: 30.3; p < 0.01) and the type of chemotherapy prior to AHSCT (odds ratio: 6.56; p < 0.05) were independent risk factors, while oral cryotherapy was the independent suppressive factor of dysgeusia (odds ratio: 0.14; p < 0.05). CONCLUSION: Our study showed that dysgeusia after AHSCT led to the decrease in oral intake and extended the TPN administration period. Moreover, MEAM or LEED chemotherapy and oral mucositis were independent risk factors for dysgeusia in patients undergoing AHSCT, while oral cryotherapy was an independent suppressive factor for dysgeusia. Therefore, oral cryotherapy should be implemented into the regimen of supportive care management in patients undergoing AHSCT.
PURPOSE:Dysgeusia is one of the sporadic adverse effects induced by chemotherapy, but it remains poorly understood. The aim of this study was to retrospectively identify the risk factors related with dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation (AHSCT). METHODS: Forty-eight patients with myeloma or lymphoma undergoing AHSCT were enrolled in this study. Data regarding dysgeusia and symptoms were collected by interviews conducted by medical workers. Patient characteristics and unfavorable effects induced by dysgeusia were obtained from medical records and analyzed. Logistic regression analysis was performed to identify the risk factors related with dysgeusia. RESULTS: Of the 48 patients, 20 (42 %) had dysgeusia after AHSCT. The total period of parenteral nutrition (TPN) administration and period of decreased oral intake in the dysgeusia group were statistically longer than those in the non-dysgeusia group. Multivariate analyses revealed that oral mucositis (odds ratio: 30.3; p < 0.01) and the type of chemotherapy prior to AHSCT (odds ratio: 6.56; p < 0.05) were independent risk factors, while oral cryotherapy was the independent suppressive factor of dysgeusia (odds ratio: 0.14; p < 0.05). CONCLUSION: Our study showed that dysgeusia after AHSCT led to the decrease in oral intake and extended the TPN administration period. Moreover, MEAM or LEED chemotherapy and oral mucositis were independent risk factors for dysgeusia in patients undergoing AHSCT, while oral cryotherapy was an independent suppressive factor for dysgeusia. Therefore, oral cryotherapy should be implemented into the regimen of supportive care management in patients undergoing AHSCT.
Authors: Noel Milpied; Eric Deconinck; Fanny Gaillard; Vincent Delwail; Charles Foussard; Christian Berthou; Remy Gressin; Virginie Lucas; Philippe Colombat; Jean-Luc Harousseau Journal: N Engl J Med Date: 2004-03-25 Impact factor: 91.245
Authors: R S Wickham; M Rehwaldt; C Kefer; S Shott; K Abbas; E Glynn-Tucker; C Potter; C Blendowski Journal: Oncol Nurs Forum Date: 1999-05 Impact factor: 2.172
Authors: Nicolaus Kröger; Rainer Schwerdtfeger; Michael Kiehl; Herbert Gottfried Sayer; Helmut Renges; Tatjana Zabelina; Boris Fehse; Florian Tögel; Georg Wittkowsky; Rolf Kuse; Axel Rolf Zander Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: M Elvira P Correa; Karis Kin Fong Cheng; Karen Chiang; Abhishek Kandwal; Charles L Loprinzi; Takehiko Mori; Carin Potting; Tanya Rouleau; Juan J Toro; Vinisha Ranna; Anusha Vaddi; Douglas E Peterson; Paolo Bossi; Rajesh V Lalla; Sharon Elad Journal: Support Care Cancer Date: 2019-12-14 Impact factor: 3.603
Authors: Cássia Emanuella Nóbrega Malta; Joyce Ohana de Lima Martins; Anna Clara Aragão Matos Carlos; Milena Oliveira Freitas; Iana Aragão Magalhães; Hérica Cristina Alves de Vasconcelos; Isabelly Joyce de Lima Silva-Fernandes; Paulo Goberlânio de Barros Silva Journal: Support Care Cancer Date: 2021-07-20 Impact factor: 3.603